BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis
NASDAQ:BMRN - Nasdaq - US09061G1013 - Common Stock - Currency: USD
BMRN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. BMRN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. BMRN may be a bit undervalued, certainly considering the very reasonable score on growth These ratings would make BMRN suitable for value and quality investing!
1. Profitability
1.1 Basic Checks
BMRN had positive earnings in the past year.
In the past year BMRN had a positive cash flow from operations.
Of the past 5 years BMRN 4 years were profitable.
In the past 5 years BMRN always reported a positive cash flow from operatings.
1.2 Ratios
BMRN has a Return On Assets of 7.33%. This is amongst the best in the industry. BMRN outperforms 93.33% of its industry peers.
Looking at the Return On Equity, with a value of 9.04%, BMRN belongs to the top of the industry, outperforming 93.87% of the companies in the same industry.
BMRN's Return On Invested Capital of 9.16% is amongst the best of the industry. BMRN outperforms 94.59% of its industry peers.
BMRN had an Average Return On Invested Capital over the past 3 years of 3.73%. This is significantly below the industry average of 14.78%.
The last Return On Invested Capital (9.16%) for BMRN is above the 3 year average (3.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.33% | ||
| ROE | 9.04% | ||
| ROIC | 9.16% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of BMRN (17.76%) is better than 95.14% of its industry peers.
With an excellent Operating Margin value of 24.13%, BMRN belongs to the best of the industry, outperforming 96.40% of the companies in the same industry.
BMRN has a Gross Margin of 79.44%. This is amongst the best in the industry. BMRN outperforms 85.05% of its industry peers.
In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.13% | ||
| PM (TTM) | 17.76% | ||
| GM | 79.44% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
BMRN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BMRN has more shares outstanding
BMRN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BMRN has been reduced compared to a year ago.
2.2 Solvency
BMRN has an Altman-Z score of 6.10. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
BMRN has a Altman-Z score of 6.10. This is in the better half of the industry: BMRN outperforms 79.28% of its industry peers.
BMRN has a debt to FCF ratio of 0.96. This is a very positive value and a sign of high solvency as it would only need 0.96 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.96, BMRN belongs to the top of the industry, outperforming 94.95% of the companies in the same industry.
A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
The Debt to Equity ratio of BMRN (0.10) is worse than 65.41% of its industry peers.
Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.96 | ||
| Altman-Z | 6.1 |
ROIC/WACC0.98
WACC9.34%
2.3 Liquidity
BMRN has a Current Ratio of 5.52. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
BMRN's Current ratio of 5.52 is in line compared to the rest of the industry. BMRN outperforms 56.94% of its industry peers.
A Quick Ratio of 3.49 indicates that BMRN has no problem at all paying its short term obligations.
BMRN has a Quick ratio (3.49) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.52 | ||
| Quick Ratio | 3.49 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 136.84% over the past year.
BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.36%.
BMRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.86% yearly.
EPS 1Y (TTM)136.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.52%
Revenue 1Y (TTM)19.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%14.84%
3.2 Future
The Earnings Per Share is expected to grow by 28.03% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 7.68% on average over the next years.
EPS Next Y59.49%
EPS Next 2Y41.11%
EPS Next 3Y33.38%
EPS Next 5Y28.03%
Revenue Next Year11.37%
Revenue Next 2Y10.68%
Revenue Next 3Y9.93%
Revenue Next 5Y7.68%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.30 indicates a rather expensive valuation of BMRN.
Compared to the rest of the industry, the Price/Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 94.95% of the companies listed in the same industry.
BMRN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.45.
A Price/Forward Earnings ratio of 13.07 indicates a correct valuation of BMRN.
95.14% of the companies in the same industry are more expensive than BMRN, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.90. BMRN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.3 | ||
| Fwd PE | 13.07 |
4.2 Price Multiples
BMRN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BMRN is cheaper than 96.22% of the companies in the same industry.
94.59% of the companies in the same industry are more expensive than BMRN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.78 | ||
| EV/EBITDA | 12.61 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BMRN has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 33.38% in the coming years.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y41.11%
EPS Next 3Y33.38%
5. Dividend
5.1 Amount
BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
57.5
+0.33 (+0.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.9%
Inst Owner Change0.92%
Ins Owners0.66%
Ins Owner Change8.7%
Market Cap11.03B
Analysts82.86
Price Target97.86 (70.19%)
Short Float %2.32%
Short Ratio2.11
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.95%
Min EPS beat(2)18.43%
Max EPS beat(2)31.48%
EPS beat(4)4
Avg EPS beat(4)27.84%
Min EPS beat(4)4.22%
Max EPS beat(4)57.23%
EPS beat(8)6
Avg EPS beat(8)15.96%
EPS beat(12)9
Avg EPS beat(12)-4.68%
EPS beat(16)13
Avg EPS beat(16)7.99%
Revenue beat(2)1
Avg Revenue beat(2)0.66%
Min Revenue beat(2)-1.37%
Max Revenue beat(2)2.69%
Revenue beat(4)3
Avg Revenue beat(4)2.79%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)5.44%
Revenue beat(8)3
Avg Revenue beat(8)-0.01%
Revenue beat(12)5
Avg Revenue beat(12)-0.3%
Revenue beat(16)7
Avg Revenue beat(16)-0.11%
PT rev (1m)-0.12%
PT rev (3m)-0.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.65%
EPS NY rev (1m)1.98%
EPS NY rev (3m)10.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.02%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.3 | ||
| Fwd PE | 13.07 | ||
| P/S | 3.74 | ||
| P/FCF | 17.78 | ||
| P/OCF | 15.75 | ||
| P/B | 1.9 | ||
| P/tB | 2.06 | ||
| EV/EBITDA | 12.61 |
EPS(TTM)2.7
EY4.7%
EPS(NY)4.4
Fwd EY7.65%
FCF(TTM)3.23
FCFY5.62%
OCF(TTM)3.65
OCFY6.35%
SpS15.38
BVpS30.21
TBVpS27.9
PEG (NY)0.36
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.33% | ||
| ROE | 9.04% | ||
| ROCE | 10.92% | ||
| ROIC | 9.16% | ||
| ROICexc | 11.38% | ||
| ROICexgc | 12.43% | ||
| OM | 24.13% | ||
| PM (TTM) | 17.76% | ||
| GM | 79.44% | ||
| FCFM | 21.02% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.96 | ||
| Debt/EBITDA | 0.74 | ||
| Cap/Depr | 87.86% | ||
| Cap/Sales | 2.71% | ||
| Interest Coverage | 79.64 | ||
| Cash Conversion | 87.19% | ||
| Profit Quality | 118.38% | ||
| Current Ratio | 5.52 | ||
| Quick Ratio | 3.49 | ||
| Altman-Z | 6.1 |
F-Score8
WACC9.34%
ROIC/WACC0.98
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)136.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.52%
EPS Next Y59.49%
EPS Next 2Y41.11%
EPS Next 3Y33.38%
EPS Next 5Y28.03%
Revenue 1Y (TTM)19.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%14.84%
Revenue Next Year11.37%
Revenue Next 2Y10.68%
Revenue Next 3Y9.93%
Revenue Next 5Y7.68%
EBIT growth 1Y301.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year102.12%
EBIT Next 3Y41.83%
EBIT Next 5Y23.16%
FCF growth 1Y2744.87%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y375.08%
OCF growth 3Y23.45%
OCF growth 5Y63.99%